NS Pharma Announces FDA Clearance of IND for Clinical Trial of NS-089/NCNP-02 Exon 44 Skipping Candidate
PPMD is excited to share that NS Pharma has announced that they have received clearance from the FDA on their Investigational New Drug (IND) application for NS-089/NCNP-02, a potential exon skipping therapy targeting people with…Learn More
